Treatment of patients with advanced gastric carcinoma with a 5- fluorouracil-based or a cisplatin-based regimen: Two parallel randomized phase II studies

Cancer

Volumn 82, Issue 8, 1998, Pages 1460-1467

  Barone, Carlo ^a   Corsi, Domenico C ^a   Pozzo, Carmelo ^a   Cassano, Alessandra ^a   Fontana, Tecla ^a   Noviello, Maria R ^a   Landriscina, Matteo ^a   Colloca, Giuseppe ^a   Astone, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

5 fluorouracil; Advanced gastric carcinoma; Cisplatin; Combination chemotherapy; Epirubicin; Etoposide; Prognostic factors

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LONIDAMINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; INDAZOLES; LEUCOVORIN; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032523070     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1460::AID-CNCR5>3.0.CO;2-D     Document Type: Article

References (41)

1. Findlay M, Cunningham D. Current advances in the treatment of gastrointestinal malignancy. Crit Rev Oncol Hematol 1993;14:127-52.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodriguez MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Cullinam SA, Moertel CG, Fleming TR, Everson L, Krook J, Schutt A, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061-7.
5. Morgan RG. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 1989;63 (S6):1008-12.
6. Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990;47:1-19.
7. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-96.
8. Berenberg JL, Goodman PJ, Oishi N, Fleming T, Natale RB, Hutchins LH. 5-fluorouracil (5-FU), and folinic acid (FA) for the treatment of metastatic gastric cancer. Proc Am Soc Clin Oncol 1989;8:101.
9. Arbuck SG, Douglass HO Jr., Trave F, Milliron S, Baroni M, Nava H. A phase II trial of 5-fluorouracil and high dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 1987;5:1150-6.
10. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke J, et al. A phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
11. Barone C, Cassano A, Astone A, Ricevuto E, Fontana T, Noviello MR, et al. Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. Oncology 1991;48:353-5.
12. Bruckner HW, Chesser MR, Wong H, Mandeli J. Folate biochemical modulation regimen for the treatment of gastric cancer. J Clin Gastroenterol 1991;13:384-9.
13. Louvet C, de Gramont A, Beerblock K, Mal F, Ciribilli JM, Varette C, et al. Hydroxyurea, folinic acid, 5-FU bolus and infusion (HLFP regimen) in advanced gastric cancer. Eur J Cancer 1995;31A (Suppl 5):119.
14. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil, combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
15. Rougier Ph, Wils J, Wilke H, Lacave A, Van Cutsem E, Vanhöfer U, et al. Advanced gastric cancer: comparison of FAMTX (5FU, Adriamycine, Methotrexate) versus ELF (Etoposide, 5FU, Leucovorin) versus FUP (infusional FU + Cisplatin). Results from an EORTC trial of the GITCCG and the Arbeitsgemeinschaft für Innere Onkologie (AIO). Eur J Cancer 1995;31A(Suppl 5):116.
16. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing Epirubicin, Cisplatin, and Fluorouracil versus Fluorouracil, Doxorubicin, and Methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
17. Del Bufalo D, Zupi G. In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell lines. Int J Oncol 1994;4:737-40.
18. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992;52:813-7.
19. Calabresi F, Marolla P, Di Lauro L, Gallo Curcio C, Paoletti G, Lombardi A, et al. Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. Int J Oncol 1994;4:753-60.
20. Tomirotti M, Bernardo G, Epifani C, Biasioli R, Franchi R, Mensi F, et al. Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 1993;3:213-7.
21. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
22. Miller AB, Hoogstarten B, Staquet M, Winckler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
23. Kaplan EL, Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized trials requiring prolonged observation in each patient. Analysis and examples. Br J Cancer 1977;31:1-39.
25. Shuster JJ. EXACTB and CONF: exact unconditional procedures for binomial data. Statistician 1988;48:234-5.
26. Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC, Mc Ardle CS. Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg 1987;74:715-20.
27. Rubens RD, Towlson KE, Ramirez AJ, Coltart S, Slevin ML, Terrel C, et al. Appropriate chemotherapy for palliating advanced cancer. BMJ 1992;304:35-40.
28. Comis RL, Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974;1:221-38.
29. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988;11:461-4.
30. Colucci G, Maiello E, Gebbia V, Cifarelli RA, Biglietto M, Pedicini A, et al. Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma: a multicentric phase II study of the Southern Italy Oncology Group (GOIM). Oncology 1996;53:269-74.
31. Macdonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979;44:42-7.
32. Gohmann JJ, MacDonald JS. Chemotherapy of gastric cancer. Cancer Invest 1989;7(1):39-52.
33. Klein H, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H, Gross R. High dose MTX/5-FU and Adriamycin for gastric cancer. Semin Oncol 1983;10 (2):1372-81.
34. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
35. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994;12:412-6.
36. Gonzalez-Baron M, Feliu J, Espinosa E, Garcia-Giron C, Chacon I, Garrido P, et al. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group. Cancer Chemother Pharmacol 1995;30:255-8.
37. Cervantes A, Villar-Grimalt A, Abad A, Anton-Torres A, Belon J, Dorta J, et al. 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1993;4:753-7.
38. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
39. Colucci G, Giotta F, Maiello E, Cifarelli RA, Leo S, Giuliani F, et al. Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. Am J Clin Oncol 1995;18:519-24.
40. Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, et al. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. Cancer 1995;76:715-9.
41. Lerner A, Gonin R, Steele GD, Mayer RJ. Etoposide, doxorubicin and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 1992; 10:536-40.